Zinc supplementation has no effect on lipoprotein metabolism, hemostasis, and putative indices of copper status in healthy men

Maxine P Bonham, Jacqueline O'Connor, Liadhan McAnena, PM Walsh, Stephen Downes, BM Hannigan, JJ Strain

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Pharmacological doses of zinc can adversely affect body copper status. The resulting copper deficiency can impact directly upon cholesterol metabolism and a suboptimal copper status has been observed to influence markers of hemostasis (specifically fibrinogen and the copper-containing coagulation factors V and VIII). The aim of this investigation was to examine the effect of a low level of zinc supplementation, to include dietary intake, at the United States tolerable upper intake level of 40 mg/d upon indicators of lipid metabolism, hemostasis, and copper. Thirty-eight subjects were recruited onto a double-blind placebo-controlled intervention trial and randomly selected to one of two groups. Group 1 took zinc supplements (30 mg/d) for 14 wk followed by copper supplements (3 mg/d) for 8 wk (to counteract adverse effects, if any, of zinc supplementation). A second group took placebo supplements for the full duration of the trial. Estimated dietary zinc intake approximated 10 mg/d. The effect of supplement was analyzed by repeated-measures analysis of variance (anova). Results indicate that no effect of zinc supplementation on putative indices of copper status, lipoprotein metabolism, and markers of hemostasis. These results indicate that short-term low-level zinc supplementation (total intake 40 mg/d) is not detrimental to health.
LanguageEnglish
Pages75-86
JournalBiological Trace Element Research
Volume93
Issue number1-3
Publication statusPublished - 2003

Fingerprint

Hemostasis
Lipoproteins
Zinc
Copper
Placebos
Factor V
Factor VIII
Lipid Metabolism
Fibrinogen
Analysis of Variance
Cholesterol
Pharmacology
Health

Cite this

Bonham, Maxine P ; O'Connor, Jacqueline ; McAnena, Liadhan ; Walsh, PM ; Downes, Stephen ; Hannigan, BM ; Strain, JJ. / Zinc supplementation has no effect on lipoprotein metabolism, hemostasis, and putative indices of copper status in healthy men. In: Biological Trace Element Research. 2003 ; Vol. 93, No. 1-3. pp. 75-86.
@article{00635e2ff8d44f24b48ce18fdf3a38df,
title = "Zinc supplementation has no effect on lipoprotein metabolism, hemostasis, and putative indices of copper status in healthy men",
abstract = "Pharmacological doses of zinc can adversely affect body copper status. The resulting copper deficiency can impact directly upon cholesterol metabolism and a suboptimal copper status has been observed to influence markers of hemostasis (specifically fibrinogen and the copper-containing coagulation factors V and VIII). The aim of this investigation was to examine the effect of a low level of zinc supplementation, to include dietary intake, at the United States tolerable upper intake level of 40 mg/d upon indicators of lipid metabolism, hemostasis, and copper. Thirty-eight subjects were recruited onto a double-blind placebo-controlled intervention trial and randomly selected to one of two groups. Group 1 took zinc supplements (30 mg/d) for 14 wk followed by copper supplements (3 mg/d) for 8 wk (to counteract adverse effects, if any, of zinc supplementation). A second group took placebo supplements for the full duration of the trial. Estimated dietary zinc intake approximated 10 mg/d. The effect of supplement was analyzed by repeated-measures analysis of variance (anova). Results indicate that no effect of zinc supplementation on putative indices of copper status, lipoprotein metabolism, and markers of hemostasis. These results indicate that short-term low-level zinc supplementation (total intake 40 mg/d) is not detrimental to health.",
author = "Bonham, {Maxine P} and Jacqueline O'Connor and Liadhan McAnena and PM Walsh and Stephen Downes and BM Hannigan and JJ Strain",
year = "2003",
language = "English",
volume = "93",
pages = "75--86",
journal = "Biological Trace Element Research",
issn = "0163-4984",
number = "1-3",

}

Zinc supplementation has no effect on lipoprotein metabolism, hemostasis, and putative indices of copper status in healthy men. / Bonham, Maxine P; O'Connor, Jacqueline; McAnena, Liadhan; Walsh, PM; Downes, Stephen; Hannigan, BM; Strain, JJ.

In: Biological Trace Element Research, Vol. 93, No. 1-3, 2003, p. 75-86.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Zinc supplementation has no effect on lipoprotein metabolism, hemostasis, and putative indices of copper status in healthy men

AU - Bonham, Maxine P

AU - O'Connor, Jacqueline

AU - McAnena, Liadhan

AU - Walsh, PM

AU - Downes, Stephen

AU - Hannigan, BM

AU - Strain, JJ

PY - 2003

Y1 - 2003

N2 - Pharmacological doses of zinc can adversely affect body copper status. The resulting copper deficiency can impact directly upon cholesterol metabolism and a suboptimal copper status has been observed to influence markers of hemostasis (specifically fibrinogen and the copper-containing coagulation factors V and VIII). The aim of this investigation was to examine the effect of a low level of zinc supplementation, to include dietary intake, at the United States tolerable upper intake level of 40 mg/d upon indicators of lipid metabolism, hemostasis, and copper. Thirty-eight subjects were recruited onto a double-blind placebo-controlled intervention trial and randomly selected to one of two groups. Group 1 took zinc supplements (30 mg/d) for 14 wk followed by copper supplements (3 mg/d) for 8 wk (to counteract adverse effects, if any, of zinc supplementation). A second group took placebo supplements for the full duration of the trial. Estimated dietary zinc intake approximated 10 mg/d. The effect of supplement was analyzed by repeated-measures analysis of variance (anova). Results indicate that no effect of zinc supplementation on putative indices of copper status, lipoprotein metabolism, and markers of hemostasis. These results indicate that short-term low-level zinc supplementation (total intake 40 mg/d) is not detrimental to health.

AB - Pharmacological doses of zinc can adversely affect body copper status. The resulting copper deficiency can impact directly upon cholesterol metabolism and a suboptimal copper status has been observed to influence markers of hemostasis (specifically fibrinogen and the copper-containing coagulation factors V and VIII). The aim of this investigation was to examine the effect of a low level of zinc supplementation, to include dietary intake, at the United States tolerable upper intake level of 40 mg/d upon indicators of lipid metabolism, hemostasis, and copper. Thirty-eight subjects were recruited onto a double-blind placebo-controlled intervention trial and randomly selected to one of two groups. Group 1 took zinc supplements (30 mg/d) for 14 wk followed by copper supplements (3 mg/d) for 8 wk (to counteract adverse effects, if any, of zinc supplementation). A second group took placebo supplements for the full duration of the trial. Estimated dietary zinc intake approximated 10 mg/d. The effect of supplement was analyzed by repeated-measures analysis of variance (anova). Results indicate that no effect of zinc supplementation on putative indices of copper status, lipoprotein metabolism, and markers of hemostasis. These results indicate that short-term low-level zinc supplementation (total intake 40 mg/d) is not detrimental to health.

M3 - Article

VL - 93

SP - 75

EP - 86

JO - Biological Trace Element Research

T2 - Biological Trace Element Research

JF - Biological Trace Element Research

SN - 0163-4984

IS - 1-3

ER -